NEW
YORK, May 12, 2023 /PRNewswire/ -- Jakubowitz
Law announces that an investigation into potential securities fraud
allegations has commenced on behalf of shareholders of Relmada
Therapeutics, Inc. (NYSE: RLMD)
To be contacted by a member of our team, fill out the
form:
https://claimyourloss.com/securities/relmada-class-action-loss-submission-form/?from=4
Further details on the investigation: Before market
opened on October 13, 2022, Relmada
announced the results of its RELIANCE III study (REL-1017-303),
evaluating the drug REL-1017 as a monotherapy for Major Depressive
Disorder (MDD). Relmada revealed that the RELIANCE III trial did
not achieve its primary endpoint, which was a statistically
significant improvement in depression symptoms compared to placebo
on Day 28, as measured by the Mongomery-Asberg Depression Rating
Scale (MADRS). Specifically, the REL-1017 treatment showed a MADRS
reduction of 14.8 points at Day 28 versus 13.9 points for placebo,
a higher-than-expected placebo response. Relmada described that
"[p]aradoxical results were observed in certain study sites, where
placebo dramatically outperformed REL-1017."
Following this news, Relmada's stock price fell nearly 80% to
close at $6.48 per share on
October 13, 2022.
Jakubowitz Law is vigorous in pursuit of justice for
shareholders who have been the victim of securities fraud. Attorney
advertising. Prior results do not guarantee similar outcomes.
CONTACT:
JAKUBOWITZ LAW
1140 Avenue of the Americas
9th Floor
New York, New York 10036
T: (628) 895-0423
F: (212) 537-5887
View original
content:https://www.prnewswire.com/news-releases/rlmd-fraud-alert-jakubowitz-law-is-investigating-relmada-therapeutics-inc-in-connection-with-potential-violations-of-federal-securities-laws-301815633.html
SOURCE Jakubowitz Law
